Shares of Nanexa, a Stockholm‑based drug‑delivery specialist, jumped roughly 122% in early Friday trading following the announcement of a landmark licensing agreement with Novo Nordisk. The deal, valued at up to about €1.17 billion ($1.33 billion), gives Novo exclusive rights to Nanexa’s PharmaShell technology for up to five development programmes.
Deal details and financial structure
Under the agreement, Novo will lead global development and commercialisation of products that incorporate the ultra‑thin coating technology, which controls drug release over time. The partnership targets formulations that can be administered monthly or quarterly, reducing the frequency of injections for chronic conditions such as obesity, type‑2 diabetes and other cardiometabolic diseases.
The financial terms include an upfront payment and a series of development and regulatory milestones totalling €615 million. The remaining value is tied to sales milestones, and Nanexa will receive a low single‑digit percentage royalty on worldwide sales of any products that emerge from the collaboration.
Market reaction
Investors responded enthusiastically, pushing Nanexa’s share price to its highest level in more than five years. The surge reflects confidence that the partnership will unlock significant revenue streams for the Swedish firm and accelerate the rollout of next‑generation injectable therapies.
Strategic significance
For Novo Nordisk, the agreement strengthens its pipeline in the rapidly growing market for long‑acting injectable medicines. By securing exclusive access to PharmaShell, Novo can potentially differentiate its products with more convenient dosing schedules, a key factor in patient adherence and market competitiveness.
Nanexa, meanwhile, gains a powerful commercial partner with global reach, providing the scale needed to bring its technology to market. The royalty structure ensures ongoing participation in the commercial success of any approved products.
Industry context
The deal arrives at a time when the pharmaceutical industry is intensifying its focus on obesity and diabetes treatments, driven by rising prevalence worldwide. Long‑acting injectables that require fewer administrations are seen as a way to improve patient outcomes and reduce healthcare costs.
Analysts note that the partnership could set a precedent for similar collaborations between technology‑focused biotech firms and large pharmaceutical companies seeking to expand their therapeutic portfolios.
Outlook
Both companies have expressed optimism about the partnership’s potential. Novo Nordisk’s spokesperson said the collaboration aligns with the company’s mission to deliver innovative, patient‑centric solutions. Nanexa’s CEO highlighted the agreement as a validation of the PharmaShell platform and a catalyst for future growth.
As the development programmes progress, market participants will watch closely for milestone payments and early clinical data that could further influence Nanexa’s valuation and the broader biotech sector.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
